CVR Announces Partnership with Dr. David J. Whellan and Thomas Jefferson University to Conduct Clinical Trials
Mittwoch, 30.11.2016 14:40 von DGAP
DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous
CVR Announces Partnership with Dr. David J. Whellan and Thomas Jefferson
University to Conduct Clinical Trials
30.11.2016 / 14:36
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2016) - CVR
Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical')
announces partnership with Dr. David J. Whellan and Thomas Jefferson
University in Philadelphia for the design and conduction of clinical trials
for its 'Carotid Stenotic Scan (CSS)' device.
Dr. Whellan is the Principal Investigator of Jefferson Regional Clinical
Center for the NIH HF Network, one of nine centers across the United States
selected to participate in a series of novel heart failure clinical trials.
Recognized as preeminent in the cardiovascular healthcare field, his
extensive clinical research has produced over 175 peer-reviewed
publications on cardiovascular disease, including cardiomyopathy, aspirin
use and coronary bypass surgery. His partnership with CVR Global signals a
much-anticipated step toward providing evidence regarding the CSS for
diagnostic accuracy. With the unique capabilities present at Thomas
Jefferson University, the study will compare CSS with existing arterial
diagnostic tools across a wide range of potential subjects. CVR executive
management looks forward to working with Dr. Whellan and the institution,
and expresses great confidence that the upcoming trials will be a thorough
and successful vetting that will position the CSS strongly ahead of its
market launch.
Commenting on this partnership, Dr. Whellan states, 'We have built a model
here at Thomas Jefferson University to engage with companies like CVR
Global in the evaluation of novel diagnostics and treatments for a wide
variety of patients. What drew us to this project is that it's a technology
that fits within our emphasis on innovation. We want to be a leading
organization for the evaluation of novel therapies and diagnostic
technologies.'
For additional information on the organization, leadership, and current
news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture
with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in
the medical industry focused on the commercialization of a proprietary
subsonic, infrasonic, and low frequency sound wave analysis technology and
has patents to a diagnostic device designed to detect and measure carotid
arterial stenosis. CVR Medical is managed by a proven technical team. CVR
Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) 'Peter Bakema'
CEO, President & Director
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves
various risks and uncertainties regarding future events related to the
Joint Venture. Such statements are subject to risks and uncertainties that
may cause actual results, performance or developments to differ materially
from those contained in the statements and are not guarantees of future
performance of the Company. No assurance can be given that any of the
events anticipated by the forward-looking statements will occur or, if they
do occur, what benefits the Company will obtain from them. These
forward-looking statements reflect management's current views and are based
on certain expectations, estimates and assumptions which may prove to be
incorrect. A number of risks and uncertainties could cause our actual
results to differ materially from those expressed or implied by the
forward-looking statements, including: (1) a downturn in general economic
conditions in North America and internationally, (2) the inherent
uncertainties and speculative nature associated with commercialization of
technology and the practice of medicine, (3) a change in health
regulations, (4) any number of events or causes which may delay or cease
commercialization and development of the Joint Venture, (5) the risk that
the Company or the Joint Venture does not execute its business plan, (6)
inability to retain key employees, (7) inability to finance operations and
growth, and (8) other factors beyond the Company's control. These
forward-looking statements are made as of the date of this news release
and, except as required by law, the Company assumes no obligation to update
these forward-looking statements, or to update the reasons why actual
results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE
CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF
THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
Click on, or paste the following link into your web browser, to view
the associated documents
http://www.newsfilecorp.com/release/23825
News Source: Newsfile
---------------------------------------------------------------------------
30.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: CVR Medical Corp.
Canada
ISIN: CA1266321084
End of News DGAP News Service
---------------------------------------------------------------------------
525557 30.11.2016